ArcDia’s Vision: Every Infection Patient Should Have Fast Access to Evidence-Based Care

A Vision More Relevant Than Ever

ArcDia’s vision is that every patient with a respiratory infection should have access to
affordable and rapid treatment based on identification of the causative
pathogen—not guesswork.

Our mission is to improve the quality, accessibility, and cost-efficiency of
infectious disease diagnostics and treatment for the benefit of society.
The identification of pathogens in acute infections should be performed by
professionals using laboratory-grade diagnostic instruments, and the results should
be available to the treating physician as quickly as possible. This enables patients to
be placed on the correct care pathway immediately. Today, this vision is more
relevant than ever, as healthcare systems urgently seek new ways to improve
efficiency and outcomes.

ArcDia’s Solution: mariPOC® Brings Laboratory-Grade Diagnostics Closer to he Patient

This vision is realized through ArcDia’s mariPOC® system and associated
healthcare service innovations. mariPOC® combines laboratory-level multipathogen
testing with automation and ease of use directly at the point of sample collection.
With mariPOC®, healthcare providers can:

• Improve the quality of clinical decision-making
• Shorten the duration of illness
• Reduce unnecessary antibiotic use
• Generate real-time population-level epidemiological data

In the long term, these benefits translate into better public health, fewer sick leaves,
and reduced healthcare costs.

It’s Time to End Guesswork in Infection Management

During the COVID-19 pandemic, our vision was realized globally for one specific
pathogen. After the pandemic, healthcare has largely reverted to old habits: many
patients with common respiratory infections are still treated empirically, without
identifying the true cause of their illness.

At the same time, entrepreneurship is increasing, particularly among sole traders
and small business owners. For entrepreneurs, every unnecessary sick day carries
economic consequences. They seek to recover themselves—and help their
employees recover—as quickly and cost-effectively as possible.

Active testing with mariPOC® is clinically significant because only by identifying
the root cause of an infection can we ensure proper and effective treatment.

Healthcare Needs a New Operating Model

In our view, current respiratory infection testing and treatment services do not yet
function efficiently enough to meet our vision—or patient needs. The threshold for
professional diagnostic testing remains too high. As a result, many patients with
acute infections do not receive appropriate diagnostic services or optimal treatment.

ArcDia’s Finnish health technology innovations help healthcare systems diagnose
and treat infections faster, more accurately, and more cost-effectively — while
simultaneously reducing the spread of epidemics in the population.

Janne O. Koskinen, PhD (Infectious Disease In Vitro Diagnostics and Biophysics)
Chief Executive Officer & Chief Scientific Officer
ArcDia International Ltd